|
Press Releases |
| Lotus Director Honored Among 2007 Health Care Heroes |
BEIJING, May 4, 2007 (PRIME NEWSWIRE) -- Lotus Pharmaceuticals, Inc. (OTC BB:LTUS.OB - News) proudly announced that its Director Mel Rothberg has been honored by The Greater Miami Chamber of Commerce's Healthcare & Bioscience Committee. Mr. Rothberg was chosen as one of the 2007 Health Care Heroes(r) whose acts of heroism represent a display of dedication to excellence in their area of expertise beyond the scope of their jobs. |
| In the field of Bio Medical, Mr. Mel Rothberg is the 2007 recipient. Mr. Rothberg has, over the last 30 years, participated in the development of the South Florida bioscience industry and is presently Chairman of Bioflorida's South Florida Bioscience Consortium. He has held executive positions in the medical device, information technology and biopharmaceutical sectors. Currently, he is Chairman and CEO of Advanced Processing and Imaging, CEO of Dharma Biomedical and CEO of Rothberg Associates, Inc. |
| s a founding director on the Lotus Board of Directors, Mr. Rothberg is committed to assisting in the growth and expansion of the Beijing-based pharmaceutical. ``Lotus Pharmaceuticals has demonstrated remarkable growth in the Chinese healthcare marketplace. I look forward to assisting Lotus in identifying additional growth opportunities that builds on the solid entrepreneurial foundation led by Dr. Liu and his team,'' commented Mr. Rothberg. |
| About Lotus Pharmaceuticals, Inc. |
| Lotus Pharmaceuticals, Inc. ("Lotus'') owns and operates Liang Fang Pharmaceutical, Ltd. ("Liang'') and En Zhe Jia Shi Pharmaceutical, Ltd. ("En Zhe''), two Chinese pharmaceutical companies located in Beijing. Liang and En Zhe form a large comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. Together, they possess some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Liang and/or En Zhe (together, "Lotus East''), and a large number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters and a warehouse of 1,000 square meters. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com. |
| Safe Harbor Statement |
| Certain statements set forth in this press release constitute ``forward-looking statements.'' Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate,'' ``project,'' ``intend,'' ``forecast,'' ``anticipate,'' ``plan,'' ``planning,'' ``expect,'' ``believe,'' ``will likely,'' ``should,'' ``could,'' ``would,'' ``may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. |
| Contact |
Lotus Pharmaceuticals, Inc.
Adam Wasserman, CFO
Tel: 877-801-0344
Fax: 954-337-2204
info@LotusEast.com |
|
